Skip to Main Content

Paper Details

PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.
Clin Cancer Res
3
2023
JAK, JAK1/2, JAK2V617F, JAK2V617F-mutant cell lines, MF, Myelofibrosis, Myeloproliferative Neoplasms, PI3K, Patients, Ruxolitinib, patients, primary myelofibrosis, ruxolitinib, umbralisib
Author NameAffiliation
Cosmin A BejanVanderbilt University School of Medicine
Paul Brent FerrellVanderbilt University School of Medicine
Paul Brent FerrellCenter for Immunobiology, Vanderbilt University School of Medicine
Paul Brent FerrellVanderbilt University School of Medicine
Paul Brent FerrellVanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine
Paul Brent FerrellVanderbilt University School of Medicine
Paul Brent FerrellVanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine
Paul Brent FerrellVanderbilt University School of Medicine
Paul Brent FerrellCenter for Immunobiology, Vanderbilt University School of Medicine
Bennett A LandmanVanderbilt University School of Medicine
Bennett A LandmanVanderbilt University School of Medicine
  • 1 - 11

Datasets

Release 1.2